ONCT - Oncternal Therapeutics' TK216 nabs Rare Pediatric Disease tag for bone cancer

The FDA grants Rare Pediatric Disease designation to Oncternal Therapeutics' (ONCT) TK216 for the treatment of Ewing sarcoma, an ultra-rare cancerous tumor that grows in the bones or soft tissue around bones.Rare Pediatric Disease designation provides for the issuance of a rare pediatric disease priority review voucher following FDA approval. The voucher can be used for accelerated approval of a future application or it can be sold to a third party.TK216 is a targeted small-molecule inhibitor of the E26 transformation-specific family of oncoproteins including fusion proteins. A Phase 1 study in Ewing sarcoma is ongoing.Shares up 9% premarket on average volume.

For further details see:

Oncternal Therapeutics' TK216 nabs Rare Pediatric Disease tag for bone cancer